Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
CEO: Stuart Essig. Company website
Integra LifeSciences Holdings Corporation (IART) trades at $15.22, up 0.79% on the day, as of Sep 20, 2026 14:58 UTC.
Integra LifeSciences Holdings Corporation has a market capitalisation of $1.18B, calculated from the live IART share price and shares outstanding.
IART has no meaningful price-to-earnings ratio: Integra LifeSciences Holdings Corporation lost $0.09 per share over the last twelve months, and a P/E is only defined on positive earnings.
Integra LifeSciences Holdings Corporation generated revenue of $1.65B over the trailing twelve months, which puts the stock at 0.72 times sales.
IART has traded between $8.70 and $20.49 over the past 52 weeks, and the last price is 25.7% below that high.
No. Integra LifeSciences Holdings Corporation is loss-making, with a net margin of -0.44% over the trailing twelve months.
Wall Street analysts rate IART Buy, with an average price target of $20.50, 34.7% above the current price.
Integra LifeSciences Holdings Corporation is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Stuart Essig is the chief executive of Integra LifeSciences Holdings Corporation, which employs 4,427 people.
QFI Terminal shows IART with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open IART in Terminal See plans